Vector-borne diseases (VBDs) are a significant public health concern in India, accounting for a substantial portion of the country's disease burden. This article provides an overview of the prevalence and management of these diseases in India, offering insights for healthcare professionals navigating this challenging landscape.
India's diverse geographical and climatic conditions create a conducive environment for various vectors, leading to a high prevalence of VBDs. Malaria, Dengue, Chikungunya, Japanese Encephalitis, and Lymphatic Filariasis are among the most prevalent VBDs. The National Vector Borne Disease Control Program (NVBDCP) reports millions of cases annually, with malaria and dengue being the most reported.
Management of VBDs is complicated by several factors including rapid urbanization, climate change, and inadequate public health infrastructure. These factors contribute to the spread of vectors and hinder effective disease control efforts. Additionally, the lack of public awareness about VBDs and their prevention further exacerbates the situation.
The Indian government, through the NVBDCP, has implemented several strategies to control VBDs. These include vector control measures, disease surveillance, early diagnosis, and prompt treatment. However, the effectiveness of these strategies is often compromised by resource constraints and systemic challenges.
Healthcare professionals play a crucial role in managing VBDs. They are at the forefront of early detection, diagnosis, and treatment of these diseases. Furthermore, they play a significant role in educating the public about disease prevention and control measures.
Understanding the prevalence and management of VBDs in India is crucial for healthcare professionals. While significant challenges exist, concerted efforts by healthcare professionals, policy makers, and the community can lead to effective control and eventual eradication of these diseases.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation